Benjamin Fairfax is an Academic Medical Oncologist based in the Department of Oncology and the MRC WIMM at the University of Oxford. His background training is in Human Immunogenetics and his clinical speciality is the treatment of skin cancer. His group is interested in teasing out systemic determinants of response to immune checkpoint blockade, primarily based on assessing features of peripheral immunity and germline genetics.’